← Central Garden & Pet Company A overview

Central Garden & Pet Company A vs The Clorox: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Central Garden & Pet Company A (CENTA)

Q3 202613 Jul – 3 Sep 2026

▲3▼1

CENTA lifts profit outlook, expands pet business with Trixie deal

Cost cuts and portfolio shift lift margins Central's Cost and Simplicity program and the exit from low-margin pet distribution pushed gross margin up sharply. Even though total sales fell 8%, organic sales rose 2% and profit margins improved, showing the business is becoming more profitable on what it sells.
Margin expansion is the main reason profit guidance was raised despite weaker sales.
Full-year profit guidance raised twice Management now expects adjusted earnings of $2.85 per share or better for fiscal 2026, up from $2.70. The raise came after a record $327 million in quarterly operating cash flow and net leverage at an all-time low of 0.5 times, giving the company room to invest and buy other businesses.
Higher guidance and a strong balance sheet directly support the stock's value.
Trixie acquisition expands European pet presence Central agreed to buy an 80% stake in German pet-treat maker Trixie for up to €400 million, moving deeper into premium pet products. The deal is expected to close in the first half of fiscal 2027 and management says more acquisitions are being considered.
The Trixie deal is a major strategic move that broadens CENTA's pet portfolio and growth prospects.
Sales decline and weak peer comparison Total revenue fell 8.2% year over year, the slowest growth among household-product peers like Spectrum Brands and WD-40. The drop is mostly from exiting the pet distribution business, but it still makes Central look like a laggard on the top line.
This is the main counterweight: weaker sales growth could worry investors even as profits rise.

August 202613 Jul – 3 Sep 2026

▲3▼1

CENTA lifts profit outlook, expands pet business with Trixie deal

Cost cuts and portfolio shift lift margins Central's Cost and Simplicity program and the exit from low-margin pet distribution pushed gross margin up sharply. Even though total sales fell 8%, organic sales rose 2% and profit margins improved, showing the business is becoming more profitable on what it sells.
Margin expansion is the main reason profit guidance was raised despite weaker sales.
Full-year profit guidance raised twice Management now expects adjusted earnings of $2.85 per share or better for fiscal 2026, up from $2.70. The raise came after a record $327 million in quarterly operating cash flow and net leverage at an all-time low of 0.5 times, giving the company room to invest and buy other businesses.
Higher guidance and a strong balance sheet directly support the stock's value.
Trixie acquisition expands European pet presence Central agreed to buy an 80% stake in German pet-treat maker Trixie for up to €400 million, moving deeper into premium pet products. The deal is expected to close in the first half of fiscal 2027 and management says more acquisitions are being considered.
The Trixie deal is a major strategic move that broadens CENTA's pet portfolio and growth prospects.
Sales decline and weak peer comparison Total revenue fell 8.2% year over year, the slowest growth among household-product peers like Spectrum Brands and WD-40. The drop is mostly from exiting the pet distribution business, but it still makes Central look like a laggard on the top line.
This is the main counterweight: weaker sales growth could worry investors even as profits rise.

Latest13 Jul – 3 Sep 2026

▲3▼1

CENTA lifts profit outlook, expands pet business with Trixie deal

Cost cuts and portfolio shift lift margins Central's Cost and Simplicity program and the exit from low-margin pet distribution pushed gross margin up sharply. Even though total sales fell 8%, organic sales rose 2% and profit margins improved, showing the business is becoming more profitable on what it sells.
Margin expansion is the main reason profit guidance was raised despite weaker sales.
Full-year profit guidance raised twice Management now expects adjusted earnings of $2.85 per share or better for fiscal 2026, up from $2.70. The raise came after a record $327 million in quarterly operating cash flow and net leverage at an all-time low of 0.5 times, giving the company room to invest and buy other businesses.
Higher guidance and a strong balance sheet directly support the stock's value.
Trixie acquisition expands European pet presence Central agreed to buy an 80% stake in German pet-treat maker Trixie for up to €400 million, moving deeper into premium pet products. The deal is expected to close in the first half of fiscal 2027 and management says more acquisitions are being considered.
The Trixie deal is a major strategic move that broadens CENTA's pet portfolio and growth prospects.
Sales decline and weak peer comparison Total revenue fell 8.2% year over year, the slowest growth among household-product peers like Spectrum Brands and WD-40. The drop is mostly from exiting the pet distribution business, but it still makes Central look like a laggard on the top line.
This is the main counterweight: weaker sales growth could worry investors even as profits rise.

The Clorox Company (CLX)

Q3 202611 Jul – 3 Oct 2026

▼2▲1

Clorox's weak core profit and soft demand overshadow GOJO-driven sales growth

Fiscal 2026 profit slump Clorox's fiscal 2026 revenue fell 5.4% and earnings per share dropped 26%, with gross margin down 290 basis points on higher manufacturing and logistics costs. This weak profit picture weighs on the stock because it shows the company's core business is struggling.
It is the latest hard evidence of the company's weak underlying profitability, directly pressuring the stock.
Soft consumer demand and inflation Management warned that inflation and value-seeking shoppers will challenge fiscal 2027, offsetting cost savings. Persistent cost inflation and soft demand could keep profits under pressure and limit the company's ability to invest in growth.
It explains the ongoing demand and cost headwinds that are a key reason the stock is under pressure.
GOJO acquisition boosts sales Clorox expects its GOJO acquisition, maker of Purell, to add about 9.5 percentage points to fiscal 2027 sales growth and be accretive to earnings. This deal is a major reason revenue is projected to rise 13-14%, giving the stock a growth catalyst.
It is the main positive force behind the sales growth outlook and a key support for the stock.
Earnings beat but guidance miss Clorox's Q2 revenue and earnings beat estimates, but its fiscal 2027 earnings guidance slightly missed expectations. The beat shows some resilience, but the soft outlook and concerns about muted category growth and market share keep a lid on the stock.
It captures the mixed near-term signals that are driving investor sentiment and the stock's recent moves.

August 202611 Jul – 3 Oct 2026

▼2▲1

Clorox's weak core profit and soft demand overshadow GOJO-driven sales growth

Fiscal 2026 profit slump Clorox's fiscal 2026 revenue fell 5.4% and earnings per share dropped 26%, with gross margin down 290 basis points on higher manufacturing and logistics costs. This weak profit picture weighs on the stock because it shows the company's core business is struggling.
It is the latest hard evidence of the company's weak underlying profitability, directly pressuring the stock.
Soft consumer demand and inflation Management warned that inflation and value-seeking shoppers will challenge fiscal 2027, offsetting cost savings. Persistent cost inflation and soft demand could keep profits under pressure and limit the company's ability to invest in growth.
It explains the ongoing demand and cost headwinds that are a key reason the stock is under pressure.
GOJO acquisition boosts sales Clorox expects its GOJO acquisition, maker of Purell, to add about 9.5 percentage points to fiscal 2027 sales growth and be accretive to earnings. This deal is a major reason revenue is projected to rise 13-14%, giving the stock a growth catalyst.
It is the main positive force behind the sales growth outlook and a key support for the stock.
Earnings beat but guidance miss Clorox's Q2 revenue and earnings beat estimates, but its fiscal 2027 earnings guidance slightly missed expectations. The beat shows some resilience, but the soft outlook and concerns about muted category growth and market share keep a lid on the stock.
It captures the mixed near-term signals that are driving investor sentiment and the stock's recent moves.

Latest11 Jul – 3 Oct 2026

▼2▲1

Clorox's weak core profit and soft demand overshadow GOJO-driven sales growth

Fiscal 2026 profit slump Clorox's fiscal 2026 revenue fell 5.4% and earnings per share dropped 26%, with gross margin down 290 basis points on higher manufacturing and logistics costs. This weak profit picture weighs on the stock because it shows the company's core business is struggling.
It is the latest hard evidence of the company's weak underlying profitability, directly pressuring the stock.
Soft consumer demand and inflation Management warned that inflation and value-seeking shoppers will challenge fiscal 2027, offsetting cost savings. Persistent cost inflation and soft demand could keep profits under pressure and limit the company's ability to invest in growth.
It explains the ongoing demand and cost headwinds that are a key reason the stock is under pressure.
GOJO acquisition boosts sales Clorox expects its GOJO acquisition, maker of Purell, to add about 9.5 percentage points to fiscal 2027 sales growth and be accretive to earnings. This deal is a major reason revenue is projected to rise 13-14%, giving the stock a growth catalyst.
It is the main positive force behind the sales growth outlook and a key support for the stock.
Earnings beat but guidance miss Clorox's Q2 revenue and earnings beat estimates, but its fiscal 2027 earnings guidance slightly missed expectations. The beat shows some resilience, but the soft outlook and concerns about muted category growth and market share keep a lid on the stock.
It captures the mixed near-term signals that are driving investor sentiment and the stock's recent moves.